Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.

"Conflict of Interest Statement Korn S: AstraZeneca, GSK, Novartis, Roche, and Sanofi – honoraria for lectures and/or consultant fees; AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Roche, and Sanofi – research support. Schmidt O: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, and Teva – honoraria for lectures and/or consultant fees; AstraZeneca, Boehringer Ingelheim, GSK, Novartis, and Sanofi – research support. Timmermann H: AstraZeneca, Almirall, Astellas Pharma, Bayer, Boehringer Ingelheim, Berlin-Chemie, GSK, Leti Pharma, Meda, Mundipharma, Novartis, Nycomed, Pfizer, Sanofi, Takeda, and Teva – consultant fees. Watz H: AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, and Takeda – consultant, travel, and speaker fees. Gappa M: Aimmune, ALK, GSK, Novartis, and Sanofi – honoraria for lectures and/or consultancy fees. Radwan A: Regeneron Pharmaceuticals, Inc. – employee and shareholder. De Prado-Gómez L, Atenhan A, Barbus S, Thakur M: Sanofi – employees and may hold stocks and/or stock options in the company. Lommatzsch M: ALK, Allergopharma, AstraZeneca, Bencard Allergie, Berlin-Chemie, Boehringer Ingelheim, Bosch, Chiesi, Circassia, GSK, HAL Allergy, Janssen-Cilag, MSD, Mundipharma, Novartis, Nycomed/Takeda, Sanofi, Teva, and UCB – honoraria for lectures and/or consultant fees; AstraZeneca and Novartis – reimbursement of attendance fees for conferences and educational events and that of travel and accommodation costs; AstraZeneca, DFG, and GSK – research support; AstraZeneca and Sanofi – funding for performing clinical studies."

"The ProVENT study is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc."